KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to -$21.6 million.

  • Inovio Pharmaceuticals' Cash from Operations rose 2138.9% to -$21.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.9 million, marking a year-over-year increase of 1966.39%. This contributed to the annual value of -$104.1 million for FY2024, which is 1631.4% up from last year.
  • Inovio Pharmaceuticals' Cash from Operations amounted to -$21.6 million in Q3 2025, which was up 2138.9% from -$20.8 million recorded in Q2 2025.
  • In the past 5 years, Inovio Pharmaceuticals' Cash from Operations ranged from a high of -$19.7 million in Q4 2024 and a low of -$78.5 million during Q2 2021
  • For the 5-year period, Inovio Pharmaceuticals' Cash from Operations averaged around -$38.4 million, with its median value being -$32.3 million (2023).
  • Per our database at Business Quant, Inovio Pharmaceuticals' Cash from Operations tumbled by 18896.84% in 2021 and then surged by 5685.1% in 2023.
  • Quarter analysis of 5 years shows Inovio Pharmaceuticals' Cash from Operations stood at -$37.9 million in 2021, then rose by 4.09% to -$36.3 million in 2022, then rose by 27.69% to -$26.3 million in 2023, then rose by 25.16% to -$19.7 million in 2024, then dropped by 9.71% to -$21.6 million in 2025.
  • Its Cash from Operations was -$21.6 million in Q3 2025, compared to -$20.8 million in Q2 2025 and -$26.9 million in Q1 2025.